Table 3.
Comparison of B-cell subsets in active treatment-naïve AAV patients with HC.
| % of B-cells median (IQR) | Absolute numbers x 106/l (IQR) | |||||
|---|---|---|---|---|---|---|
| Subsets | Active (n = 14) | HC (n = 30-31) | p-value | Active (n = 12) | HC (n = 30-31) | p-value |
| B-cells (CD19+) | 6.9* (4.4–8.6) | 5.0* (3.8–7.5) | 0.2258 | 103 (49–134) | 104 (79–164) | 0.4858 |
| MZ-like B-cells | 1.8 (0.86–3.3) | 3.4 (2.5–6.2) | 0.0014 | 1.6 (0.61–3.4) | 4.1 (3.0–7.6) | 0.0003 |
| B1-like B-cells | 1.8 (0.46–1.8) | 2.3 (1.4–2.8) | 0.0013 | 0.87 (0.41–1.9) | 2.2 (1.7–3.4) | 0.0013 |
*
Proportion of total B-cells (CD19+) within the lymphocyte population.
AAV, ANCA-associated vasculitis; HC, healthy controls; MZ, marginal zone; IQR, interquartile range.
Mann-Whitney U test was used to compare two groups with independent observations. P < 0.05 is statistically significant.